SLC5A2 and type 2 diabetes mellitus: Currently, Sodium-glucose Cotransporter 2 Inhibitor (SGLT2i), which reduce blood sugar levels, are highly effective in preventing diabetic kidney disease progression and cardiovascular diseases in type 2 DM (T2DM) patients.